Skip to content

Total at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
Exelixis logo
ExelixisEXEL
Amgen logo
AmgenAMGN
Merck & Co. logo
Merck & Co.MRK

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's total.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's total?
Ionis Pharmaceuticals (IONS) reported total of $1.75B in Q1 2026.
How has Ionis Pharmaceuticals's total changed year-over-year?
Ionis Pharmaceuticals's total decreased by 8.6% year-over-year, from $1.91B to $1.75B.
What is the long-term trend for Ionis Pharmaceuticals's total?
Over 4 years (2021 to 2025), Ionis Pharmaceuticals's total has grown at a 17.1% compound annual growth rate (CAGR), from $1.25B to $2.35B.